Claim Missing Document
Check
Articles

Found 31 Documents
Search

Monoclonal Antibody Therapies for HPV-Associated Cervical Cancer: A Literature Review Dariatul Janah; Andi Yasmon
Biomedical Journal of Indonesia Vol. 12 No. 1 (2026): Vol 12, No 1, 2026
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v12i1.297

Abstract

Cervical cancer is a malignancy in gynecology attributable to human papillomavirus (HPV) infection with high prevalence and mortality caused by persistent infections of hr-HPV 16 and 18. HPV with various virulence factors can evade the immune system and integrate its genetic material into the host cell DNA. HPV replication only occurs in differentiated cells in the upper layer of the mucosal epithelium or skin developing into cancer. Globally, approximately 70% of patients diagnosed with cervical cancer present at an advanced or late stage causing therapy to be ineffective. The use of HPV-specific monoclonal antibodies for therapy with cervical cancer, as an alternative or complement will give new insight into managing the patients. The development of monoclonal antibodies having potential as an alternative therapy began to be used as a therapy in the advanced, recurrent, persistent or metastatic cervical cancer. This review specifically discusses monoclonal antibodies that have been approved by FDA for therapy against cervical cancer. In clinical trials, adding bevacizumab to combination chemotherapy extended median overall survival by 3.7 months in patients with recurrent, persistent, or metastatic cervical cancer. Pembrolizumab significantly prolonged progression-free and overall survival compared to placebo when combine to chemotherapy (with or without bevacizumab) in similar patient populations. Likewise, tisotumab-vedotin demonstrated greater over chemotherapy as second-line or third-line therapy for recurrent cervical cancer. Therefore, this article review aims to describe the types and roles of monoclonal antibodies that have potential to be used as a single or combination therapy especially chemotherapy for patients with cervical cancer.
Co-Authors . Andriansjah Abror Irsan Ade Pryta Romanauli Simaremare Agustini, Riani Anis Anis Anis Karuniawati Ardiana Kusumaningrum Ariyani Kiranasari ASRI SULFIANTI Beti Ernawati Dewi Budiman Bela Burhanuddin Burhanuddin Burhanuddin Burhanuddin Dariatul Janah Dariatul Janah Delly Chipta Lestari Delly Chipta Lestari Dewi Murniati Diah Dwi Utami Diana Natalia Diana Natalia Efendi, Ida Effendi, Ida Effiana Effiana Effiana, Effiana Elisabeth D. Harahap Elisna Syahruddin Erlina, Linda Fadilah Fadilah Fadilah FERA IBIRAHIM Fera Ibrahim Fithriyah Fithriyah Fithriyah Fithriyah Fithriyah Fithriyah Gultom, Desy A. Heri Wibowo Ibnu Agus Ariyanto Ibnu Agus Ariyanto Ika Ningsih Junita Indarti Ketut Tuti Parwati Linosefa Linosefa Lisnawati Rachmadi Lola Febriana Dewi Louisa Ivana Utami Lucky H Moehario Lucky Hartati Moehario Mardhia, Mardhia Mardhia, Mardhia Mardiastuti Mardiastuti Maria L. Rosilawati Maria L. Rosilawati Maria Lina R. Maria Lina Rosilawati Maya Ulfah Murti, Anissa Wari Ni Made Adi Tarini Ni Nengah Dwi Fatmawati Normasari Normasari Oktania Sandra Puspita Paramita, Rafika Indah Pramita G. Dwipoerwantoro Pratiwi Pujilestari Sudarmono Purba, Hastuti Handayani S Purnomosidi, Muhammad Abhi Rahayu, Ratih Ratnoglik, Suratno Lulut Rela Febriani Ria Kodariah Rifdah Hanifah Rosa, Yulia Rudyanto Sedono Safari, Dodi Salsabila, Korrie Samsuridjal Djauzi Sari Rahmayanti Simon Yosonegoro Liem SJATHA, FITHRIYAH Sudarmo, Fitrahwati Tafroji, Wisnu Teguh Sarry Hartono Thomas Robertus Tjampakasari, Conny Riana Utami, Diah Dwi VIVI SETIAWATY Winarti, Yayah Wresti Indriatmi B. Makes Wulandari, I Gusti Ayu Inten Yeva Rosana Yulia Rosa Saharman YULIANTY MUHAYAR Yusmaniar Yusmaniar Zaenab